Mersana Therapeutics Reports Q3 2025 Net Loss of $7.5 Million, Announces Proposed Acquisition

Mersana Therapeutics, Inc. reported a net loss of $7.5 million for the third quarter of 2025, a decrease from the $11.5 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss was $56.0 million, slightly higher than the $55.1 million loss reported for the same period in 2024. Collaboration revenue for the third quarter was $11.0 million, down from $12.6 million year-over-year, while total revenue for the nine months was $16.8 million, a decrease from $24.1 million in the prior year. The decline in revenue was attributed to reduced collaboration revenue from agreements with Johnson & Johnson and Merck KGaA, partially offset by increased revenue from a collaboration with GlaxoSmithKline (GSK).

The company’s operating expenses for the third quarter were $18.7 million, down from $24.7 million in the prior year, reflecting a strategic restructuring plan that included a 55% reduction in workforce. Research and development expenses decreased to $12.2 million from $14.8 million, while general and administrative expenses fell to $6.3 million from $9.9 million. The restructuring, completed by September 30, 2025, aimed to streamline operations and focus on key product candidates, particularly the development of Emi-Le, an antibody-drug conjugate targeting breast cancer.

As of September 30, 2025, Mersana had cash and cash equivalents of $56.4 million, a significant decrease from $107.8 million at the end of 2024. The company’s total assets were reported at $62.7 million, down from $144.7 million at the end of the previous fiscal year. The accumulated deficit increased to $951.5 million, reflecting the ongoing challenges in achieving profitability. Mersana's management indicated that the current cash reserves are expected to support operations into mid-2026, but there is substantial doubt about the company's ability to continue as a going concern without additional funding.

In terms of strategic developments, Mersana announced a proposed acquisition by Day One Biopharmaceuticals, Inc. on November 12, 2025. The merger agreement includes a cash offer of $25.00 per share, along with contingent value rights that could yield additional payments based on the achievement of specific milestones. This acquisition is seen as a potential pathway to secure the necessary capital for ongoing operations and development efforts, particularly as Mersana continues to focus on its clinical-stage product candidates, including Emi-Le and XMT-2056.

Looking ahead, Mersana plans to continue its clinical development activities while navigating the complexities of the biotechnology landscape. The company remains committed to its collaborations with GSK, Johnson & Johnson, and Merck KGaA, which are expected to be key revenue sources in the future. However, the uncertainty surrounding the completion of the proposed acquisition and the need for additional funding raises questions about the company's long-term viability and operational strategy.